Prosecution Insights
Last updated: April 19, 2026

Examiner: STAVROU, CONSTANTINA E

Tech Center 1600 • Art Units: 1632

This examiner grants 43% of resolved cases

Performance Statistics

43.1%
Allow Rate
-16.9% vs TC avg
146
Total Applications
+28.9%
Interview Lift
1500
Avg Prosecution Days
Based on 72 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%
§101 Eligibility
20.4%
§102 Novelty
40.4%
§103 Obviousness
31.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17604188 GENE THERAPY FOR TREATING OR PREVENTING VISUAL EFFECTS IN BATTEN DISEASE Non-Final OA RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
16975987 NANOPATTERNING FOR CONTROLLING CELL CYTOSKELETON Final Rejection NORTHWESTERN UNIVERSITY
17928355 CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF Non-Final OA MASSACHUSETTS INSTITUTE OF TECHNOLOGY
17327872 METHOD OF PRODUCING CELL-CONTAINING CONTAINER Final Rejection RICOH COMPANY, LTD.
17050999 METHODS AND COMPOSITIONS TO STIMULATE RETINAL REGENERATION Non-Final OA UNIVERSITY OF WASHINGTON
17189967 TDP-43 IN DEGENERATIVE DISEASE Final Rejection THE JOHNS HOPKINS UNIVERSITY
16500352 ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS Final Rejection The Johns Hopkins University
16707681 PRE-SHAPED ALLOGRAFT IMPLANT FOR RECONSTRUCTIVE SURGICAL USE AND METHODS OF MANUFACTURE AND USE Final Rejection Allosource
18042040 PROCESS SYSTEM FOR BIOREACTOR-BASED CLEAN MEAT PRODUCTION Non-Final OA Merck Patent GmbH
17434686 THREE-DIMENSIONAL TISSUE CONSTRUCT AND METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING CELL-CONTAINING COMPOSITION Non-Final OA The University of Osaka
18421142 COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS Non-Final OA ASTRAZENECA AB
18023289 COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS Non-Final OA UNIVERSITY HEALTH NETWORK
16632332 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES Final Rejection THE GENERAL HOSPITAL CORPORATION
17273684 USE OF MESENCHYMAL STROMAL CELL EXOSOMES IN ANTENATAL THERAPY Non-Final OA Children's Medical Center Corporation
17923055 COMPOSITIONS AND METHODS FOR PROMOTING PROLIFERATION IN CARDIOMYOCYTES Non-Final OA THE TRUSTEES OF INDIANA UNIVERSITY
18057026 Methods for Printing Functional Human Neural Tissue Final Rejection Wisconsin Alumni Research Foundation
17545416 METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES Final Rejection Wisconsin Alumni Research Foundation
17923431 METHODS AND COMPOSITIONS FOR ENRICHMENT OF TARGET CELLS Non-Final OA PLURI BIOTECH LTD.
17781265 COMPOSITIONS AND METHODS FOR GENERATION OF SINOATRIAL NODE-LIKE CELLS AND THEIR USE IN DRUG DISCOVERY Final Rejection Cornell University
17437004 GEOMETRIC INDUCTION OF PLURIPOTENCY Non-Final OA CONSIGLIO NAZIONALE DELLE RICERCHE
17045256 COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS Final Rejection ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
17474178 VITRO ASSAY FOR DRUG DISCOVERY OF VALVULAR HEART DISEASE Non-Final OA UNIVERSITY OF SOUTH CAROLINA
18220689 CELLULAR-ANTIMICROBIAL COMBINATION COMPOSITION AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS OF JOINTS AND SOFT TISSUES Non-Final OA COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
17119484 DERIVATION OF HUMAN SKIN ORGANOIDS FROM PLURIPOTENT STEM CELLS Final Rejection INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
17572618 CHIMERIC RECEPTOR THERAPY Final Rejection PRECIGEN, INC.
18268134 DOPAMINERGIC NEURON PROGENITOR CELLS OR CELL DERIVATIVES THEREOF OBTAINED FROM LINEAGE RESTRICTED PLURIPOTENT STEM CELLS Non-Final OA Aarhus Universitet
18252714 ECTOPIC CELLULAR GROWTH FACTOR EXPRESSION FOR LOW-COST PRODUCTION OF CELL-CULTURED FOODS Non-Final OA Trustees of Tufts College
18212339 METHOD FOR THREE-DIMENSIONAL CELL CULTURE USING CELL GROWTH PROMOTING COLLOID AND MASS PRODUCTION OF HIGH-CONCENTRATION EXTRACELLULAR COMPOSITION USING THE SAME Non-Final OA 3D GLOBAL BIOTECH INC.
18565003 METHODS FOR PRIMING ALLOGENEIC CULTURED KERATINOCYTE COMPOSITIONS FOR TOPICAL USE Non-Final OA Stratatech Corporation
18297581 PLATELETS LOADED WITH ANTI-CANCER AGENTS Non-Final OA Cellphire, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month